Legal Alerts/Details

Adapting Clinical Research During the COVID-19 Pandemic

April 24, 2020
  2. See 21 CFR 56.108(a)(4), 312.30(b)(2)(ii), and 812.35(a)(2).
  3. See 21 CFR 312.50, 312.53(d), 312.56(a), 812.40, 812.43(d), and 812.46.
  4. “FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” at 19-20.

©2024 Snell & Wilmer L.L.P. All rights reserved. The purpose of this publication is to provide readers with information on current topics of general interest and nothing herein shall be construed to create, offer, or memorialize the existence of an attorney-client relationship. The content should not be considered legal advice or opinion, because it may not apply to the specific facts of a particular matter. As guidance in areas is constantly changing and evolving, you should consider checking for updated guidance, or consult with legal counsel, before making any decisions.
Tabor Center | 1200 Seventeenth Street | Suite 1900 | Denver, CO 80202-5854
The material in this newsletter may not be reproduced, distributed, transmitted, cached or otherwise used, except with the written permission of Snell & Wilmer.